Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Retained Earnings (2011 - 2026)

Lite Strategy (LITS) posted Retained Earnings of -$462.3 million for Q1 2026, down 5.4% on a QoQ basis from -$438.6 million in Q4 2025, and down 15.14% year-over-year from -$544.8 million in Q1 2025.

Analysis

Lite Strategy (LITS) Retained Earnings (2011 - 2026) Analysis & Trends

Lite Strategy has reported Retained Earnings for 16 years, with the latest figure at -$462.3 million in Q1 2026.

  • On a quarterly basis, Retained Earnings fell 15.14% year-over-year to -$462.3 million in Q1 2026; TTM through Mar 2026 was -$462.3 million, a 15.14% decrease from a year earlier, with the FY2025 full-year figure at -$404.2 million, down 4.11% from the prior year.
  • Retained Earnings was -$462.3 million for Q1 2026 at Lite Strategy, down from -$438.6 million in the prior quarter.
  • The five-year high for Retained Earnings was -$349.6 million in Q3 2023, with the low at -$462.3 million in Q1 2026.
  • Average Retained Earnings over 5 years is -$393.1 million, with a median of -$396.0 million recorded in 2023.
  • The sharpest annual moves came in 2022 and 2023: Retained Earnings dropped 17.03% in 2022, then grew 10.54% in 2023.
  • Over 5 years, Retained Earnings stood at -$380.5 million in 2022, then advanced by 5.21% to -$360.7 million in 2023, then retreated by 10.59% to -$398.9 million in 2024, then retreated by 9.95% to -$438.6 million in 2025, then slipped by 5.4% to -$462.3 million in 2026.
  • The last three Retained Earnings figures came in at -$462.3 million (Q1 2026), -$438.6 million (Q4 2025), and -$407.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -22.28 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 9.53 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 15.69 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 37.62 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 558.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 5.10 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -6.33 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 20.97 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 5.13 Bn
10 Lite Strategy 38.03 Mn 30.49 Mn - -462.30 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -462.30 Mn
Dec 31, 2025 -438.60 Mn
Sep 30, 2025 -407.80 Mn
Jun 30, 2025 -404.16 Mn
Mar 31, 2025 -401.50 Mn
Dec 31, 2024 -398.90 Mn
Sep 30, 2024 -396.23 Mn
Jun 30, 2024 -388.22 Mn
Mar 31, 2024 -369.81 Mn
Dec 31, 2023 -360.70 Mn
Sep 30, 2023 -349.62 Mn
Jun 30, 2023 -406.00 Mn
Mar 31, 2023 -396.00 Mn
Dec 31, 2022 -380.53 Mn
Sep 30, 2022 -390.80 Mn
Jun 30, 2022 -374.16 Mn
Mar 31, 2022 -358.10 Mn
Dec 31, 2021 -349.40 Mn
Sep 30, 2021 -337.22 Mn
Jun 30, 2021 -319.71 Mn